NATCO PHARMA
|
|
| BOM : 524816 NSE : NATCOPHARM | |
| LT :
Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap] Debt : Low |
Updated: |
| ST :
Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
May 12,2025 |
|
Price(EOD): ₹ 834.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 14,940.52 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NATCO PHARMA | 0.5% | 8.9% | -18.7% |
| SUN PHARMACEUTICAL INDUSTRIES | -7.3% | 1.1% | 15.2% |
| DIVIS LABORATORIES | -3.5% | 12.9% | 53.4% |
| CIPLA | 0.1% | 9.2% | 6.5% |
| TORRENT PHARMACEUTICALS | -1% | 0.2% | 19.9% |
| DR REDDYS LABORATORIES | 3.1% | 9.8% | -7.6% |
| MANKIND PHARMA | 5.5% | 5% | 8.8% |
| ZYDUS LIFESCIENCES | 0.5% | 5.6% | -10.5% |
| LUPIN | -0.4% | 6.1% | 26.5% |
FUNDAMENTAL ANALYSIS OF NATCO PHARMA
[ Q(TTM): Dec2024, Y: Mar2024
Q : Last Qtr data
Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
]Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NATCO PHARMA
[As on : May 12,2025
]
| Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
8.02
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,863.70 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] 2.55
P/B Calculated based on Book Value of Rs 5,853.10 Cr
[Latest Year - Mar2024 - Consolidated Results ] 3.49
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 4,276.80 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
-48% -52% -50% |
SHARE PRICE MOMENTUM OF NATCO PHARMA
NATCO PHARMA vs SENSEX
DEBT OF NATCO PHARMA
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2024 2023 2022 Avg_3yrs |
0.06 0.03 0.09 0.06 |
0.06 0.03 0.09 0.06 |
|
[Last Annual Data : Mar2024]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF NATCO PHARMA
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2025 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF NATCO PHARMA
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
-65.37% -95.18% -79.99% -80.43% |
-37.41% -85.53% -36.13% -37.75% |
| QtrlyTrend |
-8 | |
| Latest Qtr: Dec2024 | ||
| Quarterly Result Analysis → | ||
NATCO PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE SMALLCAP | 1.6% | 6.2% | 4.3% |
| BSE 500 | 1.4% | 8.2% | 7.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100 INDEX | 1.9% | 11.3% | 0.8% |
| NIFTY500 MULTICAP MOMENTUM QUALITY 50 INDEX | 1.5% | 11.3% | NA |
| NIFTY TOTAL MARKET | 1.5% | 8.1% | 7.8% |
| NIFTY 500 | 1.4% | 8.2% | 7.9% |
| NIFTY500 MULTICAP 50:25:25 | 1.4% | 7.9% | 6.8% |
You may also like the below Video Courses
FAQ about NATCO PHARMA
Is NATCO PHARMA good for long term investment?
As on May 12,2025, the Fundamentals of NATCO PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of NATCO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NATCO PHARMA UnderValued or OverValued?
As on May 12,2025, NATCO PHARMA is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NATCO PHARMA ?
As on May 12,2025, the Intrinsic Value of NATCO PHARMA is Rs. 1,675.27 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,607.64
Fair Value [Median EV / Sales Model] : Rs. 1,728.06
Fair Value [Median Price / Sales Model] : Rs. 1,675.27
Estimated Median Fair Value of NATCO PHARMA : Rs. 1,675.27
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
